This proposal to modify the criteria for the use of an infusion pump should not be viewed as a solution to the broader access challenges facing Medicare beneficiaries who could safely receive infusion therapy at home.
NHIA submitted comments to CMS on a new proposed rule on interoperability and prior authorization for drugs. While NHIA is mostly supportive of standardizing prior authorization (PA) processes for Medicare-covered drugs, it wants CMS to know that home infusion may not fit neatly into processes designed for medical and pharmacy benefits.
NHIA strongly opposes CMS’s proposed HCPCS coding and billing unit changes for immune globulin products, arguing that the changes would create significant administrative, operational, reimbursement, and patient care challenges without providing meaningful clinical or financial benefit.
The National Home Infusion Foundation (NHIF) welcomes the 2026-2027 Board of Directors.
Last week concluded the 2026 National Home Infusion Association Annual Conference (NHIA 2026), which convened the largest gathering dedicated to the home and alternate site infusion industry in Denver, Colorado.
The National Home Infusion Association (NHIA) and Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, are pleased to announce the addition of Melinta to NHIA’s Future of Infusion Advisory Council (FIAC).
The National Home Infusion Foundation (NHIF) announces the winner and honorable mention for its Outstanding Abstract Achievement Award for 2026.
The National Home Infusion Association has announced the finalists for its 2026 Exhibitor Innovation Award. The award recognizes groundbreaking products or services that advance the home and alternate site infusion industry.
The National Home Infusion Association (NHIA) is pleased to announce the 2026 Fellow Program (FNHIA) cohort, made up of highly accomplished home and alternate site infusion professionals.
The National Home Infusion Foundation (NHIF) is proud to announce Barbara Petroff, MS, RPh, BCSCP, CAC, CSPP, IgCP, FNHIA, FASHP as the recipient of the 2026 Women in Leadership Award.
https://doi.org/10.70776/TJLU1217
Jennifer Zhao PharmD, Johns Hopkins Care at Home | Tricia Schneider PharmD, MBA, Johns Hopkins Care at Home | Krista Decker RPh, MSQA, Johns Hopkins Care at Home
Drug utilization review (DUR) systems are important for ensuring medication safety by identifying medication-related issues, such as Drug-Drug interactions and therapy duplications. While DUR
alerts support clinical decision-making, excessive or clinically irrelevant alerts can lead to alert fatigue. This can potentially cause pharmacists to overlook crucial warnings and jeopardize patient safety.
https://doi.org/10.70776/KVJG2814
Leslie Myers PharmD, IgCP, CSI Pharmacy | Elizabeth Neal RN, IgCN, CSI Pharmacy | Edward O’Bryan MD, MBA, CPE, CSI Pharmacy | Michele Way PharmD, IgCP, BCSCP, CSI Pharmacy | Taylor Cathcart RN, CSI Pharmacy | Elizabeth Duruz R.Ph., CSP, IgCP, CSI Pharmacy | James Sheets PharmD, IgCP, CSI Pharmacy | Timothy P. Walton MHS, CCRP, CSI Pharmacy
Home infusion therapy is an established alternative site of care, from a hospital or outpatient infusion center, for patients requiring administration of infusion medications through a needle or venous access device.
The National Home Infusion Association (NHIA) is proud to announce that Melissa Leone, RN, BSN, FNHIA has been selected as the recipient of the 2026 Gene Graves Lifetime Achievement Award.
The National Home Infusion Association (NHIA) is proud to announce its 2026-2027 Board of Directors. Board members serve 3-year terms as representatives for their NHIA member organization.
https://doi.org/10.70776/DGES5928
Natalie Garcia PharmD, Option Care Health | Andrew Chinn PharmD, BCSCP, Option Care Health | Cara Bivona, PharmD Option Care Health | Maria Giannakos PharmD, MBA, BCPS, BCSCP, FNHIA, Option Care Health | Christopher Roy PharmD, BCSCP, Option Care Health | Michelle Sahlani PharmD, Option Care Health | David Shepherd PharmD, CNSC, BCSCP, Option Care Health
Infliximab and its biosimilars are used to treat several chronic inflammatory conditions. While standard dosing is effective, patients can experience loss of response and require dose escalation, shortening dose intervals or higher doses.
The National Home Infusion Association (NHIA) is releasing Infusion Industry Trends, the latest assessment of the home and alternate site infusion industry’s market position. Based on claims data from a 3-year timeframe, this focused analysis shows how the industry is evolving across therapy categories and payor environments.
The National Home Infusion Foundation (NHIF) announces the finalists for its Outstanding Abstract Achievement Award for 2026. The authors of the following 4 poster abstracts will present an overview of their research project and summarize their findings during a special clinical webinar and a panel of judges will select the award recipient.
This proposal to modify the criteria for the use of an infusion pump should not be viewed as a solution to the broader access challenges facing Medicare beneficiaries who could safely receive infusion therapy at home.
NHIA submitted comments to CMS on a new proposed rule on interoperability and prior authorization for drugs. While NHIA is mostly supportive of standardizing prior authorization (PA) processes for Medicare-covered drugs, it wants CMS to know that home infusion may not fit neatly into processes designed for medical and pharmacy benefits.
NHIA strongly opposes CMS’s proposed HCPCS coding and billing unit changes for immune globulin products, arguing that the changes would create significant administrative, operational, reimbursement, and patient care challenges without providing meaningful clinical or financial benefit.
The National Home Infusion Foundation (NHIF) welcomes the 2026-2027 Board of Directors.
Last week concluded the 2026 National Home Infusion Association Annual Conference (NHIA 2026), which convened the largest gathering dedicated to the home and alternate site infusion industry in Denver, Colorado.
The National Home Infusion Association (NHIA) and Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, are pleased to announce the addition of Melinta to NHIA’s Future of Infusion Advisory Council (FIAC).
The National Home Infusion Foundation (NHIF) announces the winner and honorable mention for its Outstanding Abstract Achievement Award for 2026.
The National Home Infusion Association has announced the finalists for its 2026 Exhibitor Innovation Award. The award recognizes groundbreaking products or services that advance the home and alternate site infusion industry.
The National Home Infusion Association (NHIA) is pleased to announce the 2026 Fellow Program (FNHIA) cohort, made up of highly accomplished home and alternate site infusion professionals.
The National Home Infusion Foundation (NHIF) is proud to announce Barbara Petroff, MS, RPh, BCSCP, CAC, CSPP, IgCP, FNHIA, FASHP as the recipient of the 2026 Women in Leadership Award.
https://doi.org/10.70776/TJLU1217
Jennifer Zhao PharmD, Johns Hopkins Care at Home | Tricia Schneider PharmD, MBA, Johns Hopkins Care at Home | Krista Decker RPh, MSQA, Johns Hopkins Care at Home
Drug utilization review (DUR) systems are important for ensuring medication safety by identifying medication-related issues, such as Drug-Drug interactions and therapy duplications. While DUR
alerts support clinical decision-making, excessive or clinically irrelevant alerts can lead to alert fatigue. This can potentially cause pharmacists to overlook crucial warnings and jeopardize patient safety.
https://doi.org/10.70776/KVJG2814
Leslie Myers PharmD, IgCP, CSI Pharmacy | Elizabeth Neal RN, IgCN, CSI Pharmacy | Edward O’Bryan MD, MBA, CPE, CSI Pharmacy | Michele Way PharmD, IgCP, BCSCP, CSI Pharmacy | Taylor Cathcart RN, CSI Pharmacy | Elizabeth Duruz R.Ph., CSP, IgCP, CSI Pharmacy | James Sheets PharmD, IgCP, CSI Pharmacy | Timothy P. Walton MHS, CCRP, CSI Pharmacy
Home infusion therapy is an established alternative site of care, from a hospital or outpatient infusion center, for patients requiring administration of infusion medications through a needle or venous access device.
The National Home Infusion Association (NHIA) is proud to announce that Melissa Leone, RN, BSN, FNHIA has been selected as the recipient of the 2026 Gene Graves Lifetime Achievement Award.
The National Home Infusion Association (NHIA) is proud to announce its 2026-2027 Board of Directors. Board members serve 3-year terms as representatives for their NHIA member organization.
https://doi.org/10.70776/DGES5928
Natalie Garcia PharmD, Option Care Health | Andrew Chinn PharmD, BCSCP, Option Care Health | Cara Bivona, PharmD Option Care Health | Maria Giannakos PharmD, MBA, BCPS, BCSCP, FNHIA, Option Care Health | Christopher Roy PharmD, BCSCP, Option Care Health | Michelle Sahlani PharmD, Option Care Health | David Shepherd PharmD, CNSC, BCSCP, Option Care Health
Infliximab and its biosimilars are used to treat several chronic inflammatory conditions. While standard dosing is effective, patients can experience loss of response and require dose escalation, shortening dose intervals or higher doses.
The National Home Infusion Association (NHIA) is releasing Infusion Industry Trends, the latest assessment of the home and alternate site infusion industry’s market position. Based on claims data from a 3-year timeframe, this focused analysis shows how the industry is evolving across therapy categories and payor environments.
The National Home Infusion Foundation (NHIF) announces the finalists for its Outstanding Abstract Achievement Award for 2026. The authors of the following 4 poster abstracts will present an overview of their research project and summarize their findings during a special clinical webinar and a panel of judges will select the award recipient.
